cord blood
-
P
Trial Report REGENECYTE cord blood cell therapy in post-COVID syndrome: a phase IIa randomized, placebo-controlled trial, 2026, Huang et al
This post is about a press release in 2024. The study is now published in 2026. See post #7 A large company specialising in umbilical cord blood has conducted a successful phase 2a trial in Long Covid patients (20 LC patients, 10 controls). The UCB contains Haemopoietic Progenitor Cells (which...- Paraprosdokian
- Thread
- cord blood hematopoietic cell transplantation long covid regenecyte stem cells
- Replies: 24
- Forum: Long Covid research